Diakonos Oncology doses first patients in DOC1021 melanoma trial
Diakonos Oncology Corp. has dosed the first patients in DOC-RM, its Phase 1/2 clinical study evaluating DOC1021 (dubodencel) in patients with unresectable or metastatic melanoma that has progressed after prior treatment. The two initial sites are City of Hope in Duarte, California, and the University of Alabama at Birmingham.
The Houston-based company said no significant acute adverse events were observed in the first patients, consistent with early signals from its parallel trials in glioblastoma and pancreatic cancer. Initial safety, biomarker and clinical activity data are expected in Q4 2026.
Trial design and regulatory status
DOC-RM (NCT07288112) is a multicentre study enrolling patients who have progressed on prior therapies, including anti-PD-1 checkpoint inhibitors. Patients receive two courses of DOC1021 combined with pegylated interferon, with an optional booster dose at approximately six months. Primary and secondary endpoints cover safety, objective response rate, circulating tumour DNA and immune biomarkers in tumour tissue and peripheral blood.
A key differentiating feature of the trial is its avoidance of lymphodepleting chemotherapy and high-dose interleukin-2, allowing outpatient administration. Additional enrolment sites include Massachusetts General Hospital, Banner MD Anderson Cancer Center, UT Southwestern, HonorHealth Research Institute, the University of North Carolina and Atlantic Health. The study is part-funded by a Product Development Research Grant from the Cancer Prevention and Research Institute of Texas.
The FDA granted DOC1021 Fast Track designation for unresectable or metastatic cutaneous melanoma in May 2026. The agency has also granted Fast Track status to the same candidate for pancreatic cancer and glioblastoma, and awarded Orphan Drug Designation for the GBM programme in January 2024.
DOC1021 is a patient-derived dendritic cell therapy that combines tumour lysate and amplified tumour-derived mRNA from each patient's own tumour with autologous dendritic cells. The company positions the approach as capable of presenting the full spectrum of a patient's tumour antigens without genetic modification of immune cells.
Jay Hartenbach, President and Chief Operating Officer of Diakonos, noted that roughly half of melanoma patients progress after checkpoint inhibition, and that available subsequent options are limited as much by toxicity and cost as by efficacy.
Market context and competitive landscape
Post-checkpoint melanoma represents a genuine unmet need. Approved salvage options remain limited, and the field has seen significant interest in personalised immunotherapy approaches, including mRNA-based tumour vaccines and tumour-infiltrating lymphocyte therapies. Iovance Biotherapeutics' lifileucel, a TIL therapy approved by the FDA in February 2024 for unresectable or metastatic melanoma after progression on checkpoint inhibitors, provides a direct comparator in terms of patient population, though it requires lymphodepletion and inpatient administration. Diakonos is positioning its outpatient profile as a differentiating factor that could broaden access beyond major academic centres.
A number of academic groups and early-stage companies are also pursuing personalised dendritic cell approaches in solid tumours, so the competitive field in this modality is active. Investors will look closely at the Q4 2026 readout for signs of durable immune activation and early efficacy signals before drawing conclusions about DOC1021's position relative to more established platforms. The trial's ASCO Trial-in-Progress presentation earlier in 2026 will have raised the programme's profile among oncologists, though substantive clinical data remain outstanding.